Tag Archives: differently’

Bluebird CEO defends $1.8 million gene therapy price — ‘It’s really thinking about it differently’

Bluebird Bio CEO Nick Leschly on Friday defended the biotech company’s $ 1.8 million price tag for its new gene therapy to treat a rare genetic blood disorder. Bluebird’s therapy, Zynteglo, was approved in Europe earlier this month for patients with beta thalassemia who require regular blood transfusions to manage their disease and have no… Read More »